Clinical trials: Postmenopausal Osteoporosis
Osteoporosis
A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass
This is a double-blinded randomized study to determine the effects of treatment on biochemical markers of bone formation and bone resorption, and bone mineral density (BMD) for 6 months of treatment with EBP05 or placebo.
- Trial name
- NCT04003467
- Testing
- EBP05
- Where
- 4 sites in Israel
- Volunteers
- 161 people
- Sponsor
- Entera Bio Ltd.
Post Menopausal Osteoporosis
A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
This study will determine the rapidity of suppression of the bone resorption marker sCTX in post-menopausal women with osteoporosis.Other bone turnover markers will also be evaluated.
- Trial name
- NCT00303485
- Testing
- Vitamin D and calcium supplementation, ibandronate [Bonviva/Boniva]
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Postmenopausal Osteoporosis
Study of Transitioning From Alendronate to Denosumab
The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab.
- Trial name
- NCT00377819
- Testing
- alendronate, Denosumab (AMG 162)
- Volunteers
- 504 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)
This study was conducted among women who had previously received alendronate for 3 to 6 years during the Fracture Intervention Trial (FIT).
- Trial name
- NCT00398931
- Testing
- MK0217, alendronate sodium / Duration of Treatment : 5 Years
- Volunteers
- 1,099 people
- Sponsor
- Organon and Co
Postmenopausal Osteoporosis
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were…
- Trial name
- STRUCTURE (NCT01796301)
- Testing
- Romozosumab, Teriparatide
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 436 people
- Sponsor
- Amgen
Osteoporosis
Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
This study will evaluate the safety and treatment effect of 50 mg odanacatib (MK-0822) with Vitamin D versus placebo with Vitamin D in postmenopausal women with low bone density.
- Trial name
- NCT00729183
- Testing
- Odanacatib, Vitamin D3, Calcium supplement
- Volunteers
- 214 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
Investigation of the Effect of BONISTEIN(R) Bone Blend on Bone Mineral Density/Content and Biomarkers of Bone Health
The purpose of this study is to obtain information about the effect of a combination of genistein, PUFAs, vitamin K and D (BONISTEIN(R) bone blend) on bone health, determined as bone mass density/content and bone biomarkers after…
- Trial name
- NCT00698984
- Testing
- BONISTEIN(R) bone blend
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Osteoporosis, Postmenopausal
A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)
The purpose of this study is to see how well alendronate and calcium as compared to calcium alone increase bone density in postmenopausal women with osteoporosis
- Trial name
- NCT00398606
- Testing
- MK0217, alendronate sodium / Duration of Treatment : 2 Years, Comparator : calcium carbonate /Duration of Treatment : 2 Years
- Volunteers
- 650 people
- Sponsor
- Organon and Co
Osteopenia
A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
The primary purpose of this study was to evaluate the efficacy of oral calcitonin (rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral density at increased risk of fracture.
- Trial name
- NCT01292187
- Testing
- Oral calcitonin at dinnertime, Oral calcitonin at bedtime
- Where
- 10 sites in United States
- Volunteers
- 129 people
- Sponsor
- Tarsa Therapeutics, Inc.
Osteoporosis
The Forteo Alendronate Comparator Trial
The main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (BMD) and other osteoporosis factors in postmenopausal women with osteoporosis.
- Trial name
- FACT (NCT02416271)
- Testing
- Teriparatide, Alendronate, Calcium
- Where
- 20 sites in United States, Brazil and 2 more
- Volunteers
- 203 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using blood sampling and communication of the results at 2 months, on adherence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis.
- Trial name
- NCT00545909
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 57 sites in Austria, Belgium and 3 more
- Volunteers
- 585 people
- Sponsor
- Hoffmann-La Roche
Post-menopausal Osteoporosis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
This study is designed to provide information about the bone-anabolic response of PTH134 when administered orally, in comparison to Forsteo®, the sub-cutaneous form of teriparatide, the active ingredient in PTH134.
- Trial name
- NCT01224717
- Testing
- PTH134, Forsteo
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 104 people
- Sponsor
- Novartis
Postmenopausal Osteoporosis
Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis
This is a post-marketing drug intensive monitoring surveillance with an observational, non-interventional design. The objectives are to compare the incidence of hypercalcemia in patients with and without calcium intake (including…
- Trial name
- NCT05433207
- Testing
- Eldecalcitol soft capsules
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chugai Pharmaceutical
Osteoporosis
Osteoporosis Screening Trial
Osteoporosis is the most common disease of bone and characterized firstly by low bone mass and secondly, impaired bone microarchitecture structure resulting in reduced strength and increased risk of fracture.
- Trial name
- OSTRIA (NCT01677637)
- Where
- Greece
- Volunteers
- 5,500 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Post Menopausal Osteoporosis
ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study.
- Trial name
- NCT00545090
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 17 sites in Hong Kong, Indonesia and 3 more
- Volunteers
- 561 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Postmenopausal
Comparative Efficacy, Safety, PK, and Immunogenicity Study
this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women…
- Trial name
- NCT05853354
- Testing
- Denosumab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 392 people
- Sponsor
- Luye Pharma Group Ltd.
Post Menopausal Osteoporosis
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.
- Trial name
- NCT01732770
- Testing
- Denosumab, Zoledronic Acid
- Where
- 45 sites in United States, Australia and 5 more
- Volunteers
- 643 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.
- Trial name
- NCT00557310
- Testing
- teriparatide
- Where
- 6 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Osteoporosis, Post-Menopausal
Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, are able to produce reliable changes in the bone marker in a severe osteoporotic population
- Trial name
- NCT00532545
- Testing
- Teriparatide
- Where
- 7 sites in Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Post Menopausal Osteoporosis
A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
This 2 arm crossover study will evaluate patient reported preference for either once monthly Boniva (150mg p.o.) or once weekly risedronate (35mg p.o.).
- Trial name
- NCT00377234
- Testing
- Risedronate, ibandronate [Bonviva/Boniva]
- Where
- 48 sites in United States
- Volunteers
- 356 people
- Sponsor
- Hoffmann-La Roche